Emergent BioSolutions Inc.
EBSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeEmergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States,. With a market capitalization of $319.4M, it sits in small-cap territory. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Market Cap
$319.4M
Beta
2.29
P/E (TTM)
—
P/E (Fwd)
5.95
EPS (TTM)
$-3.40
EPS (Fwd)
$1.05
ROE
-40.3%
ROA
6.9%
Cash
$139.7M
Total Debt
$588.2M
Free CF
$40.0M
52W Change
-35.7%
Annual Financials
Cash vs Debt
Where EBS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, EBS finished 14.52% below its 150-day moving average ($7.44) and 23.37% below its 200-day moving average ($8.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EBS overbought or oversold?
At the October 20, 2026 close, EBS's RSI(14) was 42.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Emergent BioSolutions Inc. carries $588.2M in total debt against $139.7M in cash reserves — debt is roughly 4.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $40.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -40.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $1.64B (2021) to $705.2M (2025), a 57% decline worth watching.
A beta of 2.29 means EBS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EBS.